Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green tea compound and lifestyle changes may shield high-risk brains from dementia—long-term test underway

NCT ID NCT07730671

Prevention Sponsor: Barcelonabeta Brain Research Center, Pasqual Maragall Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study follows 121 people who carry the APOE-ε4 gene variant and have noticed subtle memory slips—a group at higher risk for Alzheimer's. They previously completed a 12-month program combining diet, exercise, cognitive training, and a green tea extract (EGCG). Now, researchers will check whether those benefits held up five years later by testing memory, brain scans, blood markers, and lifestyle habits. No new treatment is given; this is a long-term checkup to see if the earlier intervention made a lasting difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
epigallocatechin gallate (EGCG), a compound found in green tea, combined with a multimodal lifestyle intervention (diet, exercise, cognitive training, and vascular risk management)
What this could lead to
If the original benefits last, this could point toward a practical, drug-free way to delay or prevent Alzheimer's in high-risk individuals.
What could go wrong
This is a small follow-up study with no new intervention, so it can only observe whether past effects persist—not prove cause. Results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 121 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals who previously completed the PENSA study will constitute the target population of this study. Of the 129 participants initially enrolled in the PENSA study, 121 completed it. Participants who completed the PENSA study were allocated as follows: * 47 participants in the MLI+EGCG group * 49 participants in the MLI+placebo group * 25 participants in the CG

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria \- Any individual who has completed the PENSA study, does not meet any exclusion criteria, and provides consent is eligible to participate in this study. Exclusion Criteria Participants will be excluded from the study if they meet any of the following conditions: * A prior clinical diagnosis of dementia, regardless of etiology. * Current institutionalization (e.g., residence in nursing homes, long-term care facilities, or similar institutions). * Impaired decision-making capacity, defined as the inability to provide informed consent independently due to cognitive, legal, or medical reasons (e.g., loss of autonomy or requirement of a legal representative). * Current participation in another interventional clinical trial, or participation in an interventional clinical trial within the previous 3 months prior to baseline; unless deemed by the investigator not to interfere with PENSA+ procedures or outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Subjective cognitive decline (SCD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

subjective cognitive decline Alzheimer disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Subjective cognitive decline (SCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fundació Pasqual Maragall

    Barcelona, Catalonia, 08005, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.